Overview

Oral Steroids for Regorafenib-induced Fatigue/Malaise in Unresectable mCRC (KSCC1402/HGCSG1402)

Status:
Unknown status
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
The objective of this randomized placebo-controlled Phase 2 study is to evaluate prophylactic effects of dexamethasone for fatigue and malaise (weakness, lethargy, malaise) resulting from regorafenib treatment, as well as to assess treatment continuation of regorafenib.
Phase:
Phase 2
Details
Lead Sponsor:
Clinical Research Support Center Kyush
Treatments:
BB 1101
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Proton Pump Inhibitors